Androgen decline and outcome in castration resistant prostate cancer (mCRPC) patients treated with docetaxel (Doc), prednisone +/- bevacizumab (B).

Conference Paper

Full Text

Duke Authors

Cited Authors

  • Ryan, CJ; Dutta, S; Kelly, W; Morris, MJ; Taplin, M-E; Halabi, S

Published Date

  • October 2018

Published In

Volume / Issue

  • 29 Suppl 8 /

Start / End Page

  • viii283 -

PubMed ID

  • 32136650

Electronic International Standard Serial Number (EISSN)

  • 1569-8041

Digital Object Identifier (DOI)

  • 10.1093/annonc/mdy284.025

Conference Location

  • England